02 Sep 2024
Medicines Patent Pool
MPP signs licence agreement to increase access to nilotinib for the treatment of chronic myeloid leukaemia
On the side lines of the World Cancer Congress 2022, the Medicines Patent Pool (MPP) announced the signing of a voluntary licensing agreement with Novartis AG to increase access to nilotinib, a twice daily oral medication used to treat chronic myeloid leukaemia (CML), part of the World Health Organization Model List of Essential Medicines (WHO EML) for treatment in adults and children of at least...
02 Sep 2024